Pacific Sage Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Pacific Sage Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-308	Closed	-$238K	–	133
2026 Q1	$238K	Hold	308	–	–	0.04%	106
2025 Q4	$238K	Buy	+308	New	+$209K	0.04%	107
2025 Q1	–	Sell	-285	Closed	-$203K	–	112
2024 Q4	$203K	Hold	285	–	–	0.05%	97
2024 Q3	$300K	Hold	285	–	–	0.07%	79
2024 Q2	$300K	Buy	285 +1	+0.4%	+$969	0.07%	76
2024 Q1	$273K	Hold	284	–	–	0.07%	78
2023 Q4	$249K	Hold	284	–	–	0.07%	78
2023 Q3	$234K	Hold	284	–	–	0.07%	76
2023 Q2	$204K	Hold	284	–	–	0.06%	82
2023 Q1	$233K	Hold	284	–	–	0.08%	74
2022 Q4	$205K	Buy	+284	New	+$210K	0.07%	83

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pacific Sage Partners's REGN Position: Q2 2026 in Review

Pacific Sage Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 308 shares — an estimated $238K sold.

Pacific Sage Partners first reported a position in REGN in Q4 2022 and held it in 11 quarters. The position peaked at $300K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Pacific Sage Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Pacific Sage Partners sold 308 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $238K.
Pacific Sage Partners first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 11 quarters.
Pacific Sage Partners's Regeneron Pharmaceuticals position peaked at $300K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pacific Sage Partners's 13F filing for Q2 2026, filed 6 Aug 2026.